The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria

被引:19
作者
Zhang, Yao [1 ]
Tang, Wenjie [1 ]
Xie, Sidong [1 ]
Chen, Jingbiao [1 ]
Zhang, Linqi [1 ]
Rong, Dailin [1 ]
Kuang, Sichi [1 ]
He, Bingjun [1 ]
Wang, Jin [1 ]
机构
[1] Sun Yat Sen Univ SYSU, Affiliated Hosp 3, Dept Radiol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Liver neoplasms; Carcinoma; hepatocellular (HCC); Magnetic resonance imaging (MRI); Gadobenic acid; HEPATOCELLULAR-CARCINOMA; GADOXETIC ACID; DIAGNOSTIC PERFORMANCE; NONINVASIVE DIAGNOSIS; NODULES; LIVER; CAPSULE; DIFFERENTIATION; CIRRHOSIS; RATES;
D O I
10.1007/s00330-021-07807-y
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To determine the value of lesion hypointensity in the hepatobiliary phase (HBP) on gadobenate dimeglumine-enhanced MRI as an additional major imaging feature for diagnosis of hepatocellular carcinoma (HCC) using LI-RADS v2018 criteria. Methods Between March 2016 and August 2018, 235 patients with 250 hepatic nodules at high risk of HCC underwent gadobenate dimeglumine-enhanced MRI. Two radiologists independently evaluated the imaging features and classified the nodules based on LI-RADS v2018 criteria, and their consensus data were used to calculate the diagnostic performance of LI-RADS categories. Two modified LI-RADS definitions were as follows: (1) LI-RADS-m1: HBP hypointensity as an additional major feature; (2) LI-RADS-m2: HBP hypointensity as an alternative to "enhancing capsule" as an additional major feature. The diagnostic performance of LR-5 categories was compared using McNemar's test. Results The sensitivity and specificity for LR-5 classification using original LI-RADS v2018 criteria were 78.1% and 96.3%, respectively. Significantly improved sensitivity (82.7%; p = 0.004) with unchanged specificity (96.3%; p = 1.00) was seen for LR-5 classification using LI-RADS-m1. Similar sensitivity and specificity (82.7% and 96.3%, respectively) were also seen using LI-RADS-m2. Significantly improved sensitivity (79.5% vs. 64.0%; p = 0.031) with unchanged specificity (96.2% vs. 96.2%, p = 1.00) was seen using both LI-RADS-m1 and LI-RADS-m2 compared to the original LI-RADS v2018 for 39 HCC nodules measuring 10-19 mm. Conclusions Lesion hypointensity on gadobenate dimeglumine-enhanced HBP MRI may improve sensitivity for LR-5 classification beyond that achievable using conventional LI-RADS v2018 criteria. Lesion hypointensity may prove a suitable alternative imaging feature to enhancing capsule for accurate LR-5 classification.
引用
收藏
页码:7715 / 7724
页数:10
相关论文
共 38 条
[1]   Clinicians and surgeon survey regarding current and future versions of CT/MRI LI-RADS [J].
Alenazi, Abdullah O. ;
Elsayes, Khaled M. ;
Marks, Robert M. ;
Yacoub, Joseph H. ;
Hecht, Elizabeth M. ;
Chernyak, Victoria ;
Krishna, Satheesh ;
Surabhi, Venkatesh ;
Lee, James T. ;
Ash, Ryan ;
Cruite, Irene ;
Kielar, Ania Z. .
ABDOMINAL RADIOLOGY, 2020, 45 (08) :2603-2611
[2]   Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma [J].
Allen, Brian C. ;
Ho, Lisa M. ;
Jaffe, Tracy A. ;
Miller, Chad M. ;
Mazurowski, Maciej A. ;
Bashir, Mustafa R. .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 210 (06) :1266-1272
[3]  
American College of Radiology, 2018, LIVER IMAGING REPORT
[4]   Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma [J].
Bolondi, L ;
Gaiani, S ;
Celli, N ;
Goffieri, R ;
Grigioni, WF ;
Leoni, S ;
Venturi, AM ;
Piscaglia, F .
HEPATOLOGY, 2005, 42 (01) :27-34
[5]   MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine [J].
Burgio, Marco Dioguardi ;
Picone, Dario ;
Cabibbo, Giuseppe ;
Midiri, Massimo ;
Lagalla, Roberto ;
Brancatelli, Giuseppe .
ABDOMINAL RADIOLOGY, 2016, 41 (08) :1546-1554
[6]   A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepatocellular Carcinoma [J].
Cabibbo, Giuseppe ;
Enea, Marco ;
Attanasio, Massimo ;
Bruix, Jordi ;
Craxi, Antonio ;
Camma, Calogero .
HEPATOLOGY, 2010, 51 (04) :1274-1283
[7]   LI-RADS Version 2018 Ancillary Features at MRI [J].
Cerny, Milena ;
Chernyak, Victoria ;
Olivie, Damien ;
Billiard, Jean-Sebastien ;
Murphy-Lavallee, Jessica ;
Kielar, Ania Z. ;
Elsayes, Khaled M. ;
Bourque, Laurence ;
Hooker, Jonathan C. ;
Sirlin, Claude B. ;
Tang, An .
RADIOGRAPHICS, 2018, 38 (07) :1973-2001
[8]   Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients [J].
Chernyak, Victoria ;
Fowler, Kathryn J. ;
Kamaya, Aya ;
Kielar, Ania Z. ;
Elsayes, Khaled M. ;
Bashir, Mustafa R. ;
Kono, Yuko ;
Do, Richard K. ;
Mitchell, Donald G. ;
Singal, Amit G. ;
Tang, An ;
Sirlin, Claude B. .
RADIOLOGY, 2018, 289 (03) :816-830
[9]   Subtraction Images From Portal Venous Phase Gadoxetic Acid-Enhanced MRI for Observing Washout and Enhancing Capsule Features in LI-RADS Version 2018 [J].
Chung, Jae Won ;
Yu, Jeong-Sik ;
Choi, Jeong Min ;
Cho, Eun-Suk ;
Kim, Joo Hee ;
Chung, Jae-Joon .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2020, 214 (01) :72-80
[10]   Incorporating the hepatobiliary phase of gadobenate dimeglumine-enhanced MRI in the diagnosis of hepatocellular carcinoma: increasing the sensitivity without compromising specificity [J].
Cortis, Kelvin ;
Liotta, Rosa ;
Miraglia, Roberto ;
Caruso, Settimo ;
Tuzzolino, Fabio ;
Luca, Angelo .
ACTA RADIOLOGICA, 2016, 57 (08) :923-931